Cognition Therapeutics Files 8-K

Ticker: CGTX · Form: 8-K · Filed: Aug 28, 2024 · CIK: 1455365

Cognition Therapeutics INC 8-K Filing Summary
FieldDetail
CompanyCognition Therapeutics INC (CGTX)
Form Type8-K
Filed DateAug 28, 2024
Risk Levelmedium
Pages2
Reading Time2 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: 8-K, financial-statements, regulation-fd

Related Tickers: COGT

TL;DR

COGT filed an 8-K, likely financial updates or Reg FD news. Details TBD.

AI Summary

Cognition Therapeutics, Inc. filed an 8-K on August 28, 2024, to report on financial statements and exhibits, and for a Regulation FD Disclosure. The filing does not contain specific financial figures or details about the nature of the disclosure.

Why It Matters

This filing indicates Cognition Therapeutics is providing updates to the SEC, which could relate to financial performance or regulatory matters that may impact investors.

Risk Assessment

Risk Level: medium — The filing is an 8-K, which often contains material information, but the specific content is not detailed here, requiring further investigation.

Key Players & Entities

FAQ

What specific financial statements or exhibits are being filed with this 8-K?

The filing indicates that financial statements and exhibits are included, but the specific details of these documents are not provided in the provided text.

What is the nature of the Regulation FD Disclosure mentioned in the filing?

The filing states it is for a Regulation FD Disclosure, but the content of this disclosure is not specified in the provided text.

What is Cognition Therapeutics, Inc.'s primary standard industrial classification code?

The primary standard industrial classification code for Cognition Therapeutics, Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).

When was Cognition Therapeutics, Inc. incorporated or organized?

Cognition Therapeutics, Inc. was incorporated or organized in Delaware.

What is the address of Cognition Therapeutics, Inc.'s principal executive offices?

The address of Cognition Therapeutics, Inc.'s principal executive offices is 2500 Westchester Avenue Purchase, NY 10577.

Filing Stats: 515 words · 2 min read · ~2 pages · Grade level 11.5 · Accepted 2024-08-28 06:26:14

Key Financial Figures

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. Attached as Exhibit 99.1 and furnished for purposes of Regulation FD is a presentation that Cognition Therapeutics, Inc. may use from time to time in presentations or discussions with investors, analysts, and other parties. The information in this Item 7.01 (including Exhibit 99.1) is being furnished solely to satisfy the requirements of Regulation FD and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise Act of 1933, as amended, or the Exchange Act.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits The following exhibits are being furnished herewith: Exhibit No. Document 99.1 Investor presentation of Cognition Therapeutics, Inc. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. COGNITION THERAPEUTICS, INC. Date: August 28, 2024 By: /s/ Lisa Ricciardi Name: Lisa Ricciardi Title: President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing